Skip to content

IN2PHARMA

Active Public limited companyfounded 2008active for 18 yearsTerloonststraat 22, 1910 KampenhoutKBO/BCE: BE 0895.730.662 subsidiary of

Lifetime

18 annual accounts with figures on one time axis
peak of €2.4m in 2025
€2.4m▲ 25.9%
peak of €1.1m in 2023
€909,969▼ 7.6%
peak of €76,282 in 2009
€69,300unchanged
€1.4m▲ 11.4%
peak of 15.1 FTE in 2025
15.1 FTE▲ 33.6%
Board5 names since 2015
4 directors and 3 others
Owners
  
Documentsfilings and deeds
22-06-202639 days before the deadline
2025abbreviated format
Gross margin from €1.9m to €2.4mStaff from 11.3 FTE to 15.1 FTEDividend €909,969Investments €12,401Cash from €130,701 to €333,982

Key points

from the 2025 annual accounts

Equity

€69,300 =
69,3002024+909,969Profit-909,969Dividend69,3002025

IN2PHARMA paid out €909,969 in dividends. That is 100% of the 2025 profit.

Debts

€1.4m 95% of the balance sheet
Suppliers 13%Taxes and wages 20%Other 67%

Of this, €1.4m falls due within a year.

Investments

€12,401 11.7 times depreciation
20232025

Green is investment, beige is depreciation.

Staff

21 employees on 31-12-2025
3220222320234220241332025

In 2025, 13 employees joined and 3 left.

Board

4 joined · 1 left

4 directors joined and 1 left, the latest change on 13-04-2026. 4 are in office now.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 537 companies had the same profile as IN2PHARMA has now. Each dot stands for 2 companies, two years later.

95.9%
were still trading
3.4%
stopped another way
0.7%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 537 companies, not a prediction for IN2PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 02-04-2026
Director, since 02-04-2026
Director, since 02-04-2026
Director,
  • 100%score equity €100,896 (2025) · deed of 12-02-2026
Board & ownership

Recent changes

3 directors appointed, 1 resignation changes role from managing director to day-to-day manager · resigns · , and appointed · Board meeting of 13-04-2026 · Gazette deed
Merger: IN2PHARMA takes over Studio Pharma and KDT Consulting Dissolution of the company · Dissolved without liquidation · The company holds all the shares of Studio Pharma · General meeting of 02-04-2026 · Gazette deed
New establishment in Ghent Kerkstraat 108
Merger proposal: IN2Pharma takes over Studio Pharma and KDT Consulting holds all the shares · Gazette deed
All 32 events

Comparable companies

same main activity, similar in size and age
Company
IN2PHARMA Kampenhout €1.5m €2.4m 4.7% 15.1
ESQ SOLUTIONS Kruisem €2.0m €2.0m 75.2% 16.3
nexyan Brussels €1.5m €1.8m 17.0% 13
REAZN+ Kruisem €1.5m €2.4m 33.8% 22.6
HURA Beerse €1.6m €1.5m 28.9% 16.4
CUBEWISE BELGIUM Deinze €2.3m €2.0m 16.4% 13
FERN VALLEY Kontich €1.9m €2.2m 67.7% 24.1

These companies have the same main activity as IN2PHARMA: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.5m and €2.3m, founded between 2005 and 2010.

Official details

Source: KBO
Status
Active since 29-01-2008Normal situation
Activity
Business and other management consultancyNACE 70200and 1 other
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment units
2.231.419.0781910 Kampenhout, registered on 01-05-2014
2.388.528.4939050 Ghent, since 02-04-2026
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

≈ €4.5mestimated
€1.5m▲ 10.8%
Employeeson 31-12-2025
21▲ 90.9%
Filing
Filed on 22-06-2026, 39 days before the end of the filing period
Financials

Insights on IN2PHARMA

IN2PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €148,409 in 2008 to €2.4m in 2025.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about IN2PHARMA

What is the company number of IN2PHARMA?
The company number of IN2PHARMA is 0895.730.662. The VAT number is the same number with BE in front: BE 0895.730.662.
Where is IN2PHARMA based?
The registered office is at Terloonststraat 22, 1910 Kampenhout.Company details
What does IN2PHARMA do?
According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of IN2PHARMA?
IN2PHARMA is a public limited company (NV).
When was IN2PHARMA founded?
IN2PHARMA was founded on 29-01-2008.
Is IN2PHARMA still active?
Yes, IN2PHARMA is an active enterprise in the KBO register.
How many employees does IN2PHARMA have?
IN2PHARMA had an average of 15.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does IN2PHARMA fall under?
In its 2025 annual accounts, IN2PHARMA states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of IN2PHARMA?
The turnover in financial year 2025 is about €4.5m. This figure is estimated from the gross margin of €2.4m and 35 comparable companies (NACE 70200). It probably lies between €3.1m and €5.8m.
Is IN2PHARMA profitable?
In financial year 2025, IN2PHARMA made a profit of €909,969.
Where can I find the annual accounts of IN2PHARMA?
IN2PHARMA filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of IN2PHARMA due?
IN2PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.